ARCHIVES

FDA Guidance for Public Comment at Advisory Committee Meetings

This article is from The Cancer Letter archive.

Vol. 36 No. 45 | December 10, 2010

Download PDF Visit The Full Archive

Related Articles

The Cancer Letter Marks 25th Anniversary

December 18, 1998

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

June 24, 2011

Marijuana-Derived Drug Less Effective Than Standard

March 29, 2002

Cancer Screenings: American Over 50 Urged to Get Colon Caner Tests

March 5, 1999

In Breif: FDA Issues Uterine Cancer-Tamoxifin Warning; Fisher Declined Invitation To Speak At AACR

April 15, 1994

Committee Approves NDA For Tamoxifen

January 21, 1977